NewAmsterdam Pharma Co N.V (NAMS) Invested Capital: 2022-2025
Historic Invested Capital for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $772.4 million.
- NewAmsterdam Pharma Co N.V's Invested Capital rose 94.19% to $772.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $772.4 million, marking a year-over-year increase of 94.19%. This contributed to the annual value of $795.0 million for FY2024, which is 164.15% up from last year.
- As of Q3 2025, NewAmsterdam Pharma Co N.V's Invested Capital stood at $772.4 million, which was down 3.38% from $799.4 million recorded in Q2 2025.
- Over the past 5 years, NewAmsterdam Pharma Co N.V's Invested Capital peaked at $800.9 million during Q1 2025, and registered a low of $429,991 during Q2 2023.
- In the last 3 years, NewAmsterdam Pharma Co N.V's Invested Capital had a median value of $411.0 million in 2024 and averaged $495.7 million.
- In the last 5 years, NewAmsterdam Pharma Co N.V's Invested Capital tumbled by 30.69% in 2023 and then skyrocketed by 95,479.67% in 2024.
- NewAmsterdam Pharma Co N.V's Invested Capital (Quarterly) stood at $434.2 million in 2022, then slumped by 30.69% to $301.0 million in 2023, then spiked by 164.15% to $795.0 million in 2024, then surged by 94.19% to $772.4 million in 2025.
- Its Invested Capital stands at $772.4 million for Q3 2025, versus $799.4 million for Q2 2025 and $800.9 million for Q1 2025.